These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 33877274

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial.
    Rees CA, Brousseau DC, Cohen DM, Villella A, Dampier C, Brown K, Campbell A, Chumpitazi CE, Airewele G, Chang T, Denton C, Ellison A, Thompson A, Ahmad F, Bakshi N, Coleman KD, Leibovich S, Leake D, Hatabah D, Wilkinson H, Robinson M, Casper TC, Vichinsky E, Morris CR, SCD Arginine Study Group and PECARN.
    Trials; 2023 Aug 17; 24(1):538. PubMed ID: 37587492
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Magnesium for treating sickle cell disease.
    Than NN, Soe HHK, Palaniappan SK, Abas AB, De Franceschi L.
    Cochrane Database Syst Rev; 2017 Apr 14; 4(4):CD011358. PubMed ID: 28409830
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 14; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

  • 12. Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease.
    Goldman RD, Mounstephen W, Kirby-Allen M, Friedman JN.
    Pediatrics; 2013 Dec 14; 132(6):e1634-41. PubMed ID: 24276838
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study.
    Cheung AT, Chan MS, Ramanujam S, Rangaswami A, Curl K, Franklin P, Wun T.
    J Investig Med; 2004 Sep 14; 52(6):402-6. PubMed ID: 15612454
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E.
    Lancet Haematol; 2021 May 14; 8(5):e323-e333. PubMed ID: 33838113
    [Abstract] [Full Text] [Related]

  • 17. Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    Gurkan UA.
    JAMA; 2021 Sep 14; 326(10):975. PubMed ID: 34519808
    [No Abstract] [Full Text] [Related]

  • 18. Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    Kenter MJH, Cohen AF.
    JAMA; 2021 Sep 14; 326(10):974-975. PubMed ID: 34519809
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.